Additional file 1: of Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab

Ouaknine Krief, Julia; de Tauriers, Pierre Helly; Dumenil, Coraline; Neveux, Nathalie; Dumoulin, Jennifer; Giraud, Violaine; Labrune, Sylvie; Tisserand, Julie; Julie, Catherine; Emile, Jean-François; Chinet, Thierry; Leprieur, Etienne Giroux

doi:10.6084/m9.figshare.8857847.v1

40425_2019_658_MOESM1_ESM.docx (2.1 MB)

Additional file 1: of Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab

journal contribution

posted on 2019-07-10, 05:00 authored by Julia Ouaknine Krief, Pierre Helly de Tauriers, Coraline Dumenil, Nathalie Neveux, Jennifer Dumoulin, Violaine Giraud, Sylvie Labrune, Julie Tisserand, Catherine Julie, Jean-François Emile, Thierry Chinet, Etienne Giroux Leprieur

Figure S1. Repartition of the antibiotic classes in early use of antibiotics (EUA) group for each prescription (n = 51). Figure S2. Therapeutic indications of EUA (n = 51). Figure S3. Main bacteria phylum in blood at baseline in the overall population (n = 35). Figure S4. LEFSE diagram of blood microbiome at M0 according to tumor response. Figure S5. LEFSE diagram of blood microbiome at M0 according to clinical benefit Figure S6. LEFSE diagram of blood microbiome at M2 according to early use of antibiotic (EUA). (DOCX 2147 kb)